Zhi Tong Cai Jing·2026-03-31 21:38Group 1 - The core viewpoint of the article highlights the financial performance of Kailaiying for the fiscal year 2025, showing a revenue of approximately 6.67 billion RMB, representing a year-on-year growth of 14.91% [1] - The net profit attributable to shareholders is around 1.13 billion RMB, which is an increase of 19.35% compared to the previous year, with basic earnings per share at 3.16 RMB [1] - The company plans to distribute a dividend of 13.00 RMB per 10 shares (including tax) [1] Group 2 - Revenue from large pharmaceutical companies reached 2.92 billion RMB, growing by 8.36% year-on-year, while revenue from small and medium-sized pharmaceutical companies was 3.76 billion RMB, marking a 20.57% increase [1] - The company has established a shareholder dividend return plan for the next three years (2026-2028), committing to a minimum annual cash dividend ratio of 10% of distributable profits, with a minimum of 80% during mature stages without significant capital expenditures [1] - The board will seek feedback from minority shareholders through various channels to ensure that the dividend policy balances shareholder returns with sustainable company development [1]